Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2115 · 4 trials · 5 indications
To describe the AZD2115 dose-muscarinic receptor occupancy relationship in the lungs in healthy volunteers
No formal statistical tests will be performed. Abnormalities will be listed without statistical analysis
| Arm | Type | Description |
|---|---|---|
| Single dose of AZD2115 25 µg | EXPERIMENTAL | - |
| Single dose of AZD2115 80 µg | EXPERIMENTAL | - |
| Single dose of AZD2115 240 µg | EXPERIMENTAL | - |
| Single doses of placebo | PLACEBO_COMPARATOR | - |
| Single dose of indacaterol 150 µg | ACTIVE_COMPARATOR | - |
| Single dose of indacaterol 150 µg + tiotropium 18 µg | ACTIVE_COMPARATOR | - |
| AZD2115 | EXPERIMENTAL | - |
| Spiriva (Tiotropium) | ACTIVE_COMPARATOR | - |
| [11C]AZ13754366 | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | AZD2115 |
| 2 | PLACEBO_COMPARATOR | Placebo to AZD2115 |
| Name | Type | Description |
|---|---|---|
| AZD2115 | DRUG | AZD2115 administered via inhalation |
| Placebo | DRUG | Placebo administered via inhalation |
| Indacaterol | DRUG | Indacaterol administered via inhalation |
| Indacaterol + Tiotropium | DRUG | Indacaterol + Tiotropium administered inhalation |
| SPIRIVA | DRUG | Tiotropium |
| [11C]AZ13754366 | RADIATION | Radioligand |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * Male or female of non-childbearing potential (post-menopausal or surgically sterilised), age ≥40 years at Visit 1 * Clinical diagnosis of COPD for more than 1 year at Visit 1, according to GOLD guidelines *...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 5 | PHASE3 | Depemokimab |
| Sanofi SA Sponsored ADR | SNY | 7 | PHASE3 | Itepekimab |
| AstraZeneca PLC | AZN | 14 | PHASE3 | Tezepelumab |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Alpha-1 MP |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07275315 dose 1 |
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Frespaciguat |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE3 | 611 |
| Generate Biomedicines, Inc. | GENB | 1 | PHASE1 | GB-0895 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | Treprostinil |
| Pulmonx Corp. | LUNG | 3 | - | Undisclosed |
| Baxter International Inc. | BAX | 1 | N/A | Undisclosed |
| Catalyst Pharmaceuticals, Inc. | CPRX | 1 | EARLY_PHASE1 | Undisclosed |
AZD2115 is an investigational small molecule being developed for chronic obstructive pulmonary disease (COPD). It has been studied in healthy volunteers and in COPD patients to assess its safety, tolerability, and effects on the lungs. The drug is administered via inhalation and is currently in clinical development.
AZD2115 targets muscarinic receptors in the lungs, as indicated by a positron emission tomography (PET) study that measured muscarinic receptor occupancy after inhalation of AZD2115 and tiotropium. This mechanism is relevant for treating conditions like COPD that involve airway narrowing.
AZD2115 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. AstraZeneca is conducting clinical trials to evaluate the drug's safety and efficacy in respiratory conditions.
AZD2115 has completed Phase 1 and Phase 2 clinical trials. The Phase 2 study, which investigated three different doses of inhaled AZD2115 in COPD patients, has been completed. The drug is not yet approved and remains investigational, with no active trials currently listed.
AZD2115 has been studied in four completed clinical trials. These include NCT01283984, a single ascending dose study in healthy volunteers and COPD patients; NCT01445782, a multiple ascending dose study in healthy volunteers; NCT01498081, a Phase 2 study in COPD patients; and NCT03097380, a PET study in healthy volunteers.
No, AZD2115 is not the same as tiotropium. In a clinical trial, AZD2115 was compared with tiotropium to determine muscarinic receptor occupancy in the lungs. Both drugs target muscarinic receptors, but they are distinct investigational and approved products, respectively.